Linked Data API

Show Search Form

Search Results

1006964
registered interest false more like this
date less than 2018-11-14more like thismore than 2018-11-14
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Ocrelizumab more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the affordability to the NHS of ocrelizumab for the treatment of progressive multiple sclerosis. more like this
tabling member constituency Birkenhead remove filter
tabling member printed
Frank Field more like this
uin 191304 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-22more like thismore than 2018-11-22
answer text <p>The Department has made no assessment. The National Institute for Health and Care Excellence is currently developing technology appraisal guidance on the use of ocrelizumab for treating primary progressive multiple sclerosis.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
remove filter
answering member
4067
label Biography information for Steve Brine more like this
tabling member
478
label Biography information for Lord Field of Birkenhead more like this